TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD
102.38
-2.08 (-1.99%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close104.46
Open104.35
Bid73.72 x 1100
Ask104.52 x 1100
Day's Range101.99 - 104.46
52 Week Range76.93 - 121.23
Volume52,344
Avg. Volume67,961
Market Cap3.995B
Beta (3Y Monthly)0.75
PE Ratio (TTM)12.99
EPS (TTM)7.88
Earnings DateFeb 5, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-12-10
1y Target Est101.16
Trade prices are not sourced from all markets
  • Will Taro Pharmaceutical Industries Continue to Surge Higher?
    Zacks8 days ago

    Will Taro Pharmaceutical Industries Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Taro Pharmaceutical.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.

    Taro Pharmaceutical Industries Ltd NYSE:TAROView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for TARO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TARO. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding TARO totaled $1.78 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga14 days ago

    The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...

  • Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Surpass Estimates
    Zacks15 days ago

    Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Surpass Estimates

    Taro (TARO) delivered earnings and revenue surprises of 23.08% and 0.96%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    Taro: Fiscal 3Q Earnings Snapshot

    The Haifa Bay, Israel-based company said it had net income of $2.40 per share. The drug maker posted revenue of $176.4 million in the period. Taro shares have risen 10 percent since the beginning of the ...

  • Business Wire15 days ago

    Taro Provides Results for December 31, 2018

    Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the three and nine months ended December 31, 2018.

  • Business Wire21 days ago

    Taro to Announce Third Quarter Results on February 6, 2019

    Taro Pharmaceutical Industries Ltd. announced today that it plans to release its financial results for the quarter ended December 31, 2018, after the close of market on Wednesday, February 6, 2019.

  • Taro Pharmaceutical (TARO) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks22 days ago

    Taro Pharmaceutical (TARO) Reports Next Week: Wall Street Expects Earnings Growth

    Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Taro Pharmaceutical Industries Ltd.’s (NYSE:TARO) 9.9% Better Than Average?
    Simply Wall St.28 days ago

    Is Taro Pharmaceutical Industries Ltd.’s (NYSE:TARO) 9.9% Better Than Average?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...

  • Business Wirelast month

    Taro Announces Completion of $250 Million Share Repurchase Program

    Taro Pharmaceutical Industries Ltd. announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of its ordinary shares in open market transactions at an average price of $100.28 per share.

  • Do Hedge Funds Love Taro Pharmaceutical Industries Ltd. (TARO)?
    Insider Monkey2 months ago

    Do Hedge Funds Love Taro Pharmaceutical Industries Ltd. (TARO)?

    Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]

  • PR Newswire2 months ago

    U.S. FDA Approves Removal of "Not for Home Use" Label Restriction for Pliaglis®

    LAVAL, QC, Dec. 17, 2018 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Pliaglis® following its mandated six-month review process, in line with the target action date under the Prescription Drug User Fee Act (PDUFA). In 2017, Taro Pharmaceuticals Inc. (Taro), our licensee for Pliaglis in the U.S. market, completed the study to support the removal of the Pliaglis "Not for Home Use" label restriction and filed the FDA submission with the proposed label change on June 8, 2018.

  • Business Wire2 months ago

    Taro Provides Shareholders with Procedures Regarding Israeli Withholding Tax on Dividend

    Taro Pharmaceutical Industries Ltd. (TARO) (“Taro” or the “Company”) announced today an explanation regarding taxation on the $500 million Special Dividend payable on December 28, 2018 to shareholders of record at the close of business on December 11, 2018. Following the announcement by the Company on November 5, 2018, that it will pay a $500 million dividend (the “Dividend”) on December 28, 2018, and in accordance with a specific tax ruling that the Company has received from the Israeli Tax Authority ("ITA"), the Company would like to elaborate about the procedures whereby Israeli taxes will be withheld from the Dividend payment, based on conditions set by the ITA in the tax ruling.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TARO earnings conference call or presentation 6-Nov-18 1:00pm GMT

    Q2 2019 Taro Pharmaceutical Industries Ltd Earnings Call

  • Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Lag Estimates
    Zacks4 months ago

    Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Lag Estimates

    Taro (TARO) delivered earnings and revenue surprises of -18.37% and -5.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Taro: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Haifa Bay, Israel-based company said it had profit of $1.60. The drug maker posted revenue of $159 million in the period. Taro shares have dropped nearly 6 percent since the beginning ...

  • Business Wire4 months ago

    Taro Provides Results for September 30, 2018

    Board of Directors Approves $500 Million Special Dividend

  • Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
    Zacks4 months ago

    Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

    We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

  • Taro Pharmaceutical (TARO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks4 months ago

    Taro Pharmaceutical (TARO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.